Submitted:
23 June 2025
Posted:
24 June 2025
You are already at the latest version
Abstract

Keywords:
1. Introduction
2. Materials and Methods
2.1. Study Design and Database
2.2. Methods of Investigation
2.3. Data Analysis
3. Results
3.1. Frequency of Isolation and Assessment of Microbial Colonization
3.2. Properties of Isolated Cultures
3.3. Sensitivity of Isolated Cultures to Antibiotics
4. Discussion
4.1. Background
4.2. Morphological, Tinctorial, Structural, and Biological Characteristics of S. paucimobilis
4.3. Natural Sources of Infection Caused by S. paucimobilis as One of the Central Issues of Importance in Medical Practice
4.4. Sources of S. paucimobilis in the Human Habitat in Hospital and Out-of-Hospital Environments
4.5. Modes of Transmission in Hospital and Community-Acquired Exogenous Infection Caused by S. paucimobilis. Factors of Transmission
4.6. Pathogenicity Factors
4.7. A susceptible Organism
4.8. Etiotropic Therapy
5. Conclusions
- The obtained results do not confirm or refute the role of S. paucimobilis in microbial associations in the development of infectious pathology of the fauces of children with recurrent tonsillitis. However, it indicates that the presence of this species of microorganisms in the microbial landscape of the pharyngeal mucosa of children with recurrent tonsillitis is a common phenomenon, which, in particular, can be explained by age-related immune system in children.
- The high concentration of S. paucimobilis in pathological material from children with recurrent tonsillitis and the high percentage of patients with this microorganism indicate a high probability that this microorganism can be transferred from patients to the environment.
- Among the antimicrobials of choice for empirical antibiotic therapy, the best ones are the clavulanic acid-protected β-lactam antibiotics, Piperacillin Tazobactam, and Carbopenems. The anti-TB antibiotic Rifampicin is useful in cases of resistance to other antibiotics.
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Lee, J.U.; Kim, J.K.; Yun, S.H.; Park, M.S.; Lee, N.E.; Sun, I.O.; Lee, K.Y. A Case of Peritoneal Dialysis-Associated Peritonitis Caused by Sphingomonas Paucimobilis. Kidney Res. Clin. Pract. 2013, 32, 78–80. [Google Scholar] [CrossRef]
- Ryan, M.P.; Adley, C.C. Sphingomonas Paucimobilis: A Persistent Gram-Negative Nosocomial Infectious Organism. J. Hosp. Infect. 2010, 75, 153–157. [Google Scholar] [CrossRef] [PubMed]
- Toh, H.S.; Tay, H.T.; Kuar, W.K.; Weng, T.C.; Tang, H.J.; Tan, C.K. Risk Factors Associated with Sphingomonas Paucimobilis Infection. J. Microbiol. Immunol. Infect. 2011, 44, 289–295. [Google Scholar] [CrossRef] [PubMed]
- Fedorchenko, V.I.; Loban, G.A.; Gancho, O.V.; Ivakhniuk, T.V.; Bagnuk, N.A.; Dudar, A.O.; Kovalenko, N.P.; Bobrova, N.O. Modern Trends of Changes in the Microbiota of Urogenital System in Patients with Urolithiasis. Pol. Merkur. Lekarski. 2023, 51, 346–349. [Google Scholar] [CrossRef]
- Yu, F.B.; Shan, S.D.; Luo, L.P.; Guan, L.B.; Qin, H. Isolation and Characterization of a Sphingomonas Sp. Strain F-7 Degrading Fenvalerate and Its Use in Bioremediation of Contaminated Soil. J. Environ. Sci. Health. B. 2013, 48, 198–207. [Google Scholar] [CrossRef]
- Faustova, M.O.; Ananieva, M.M.; Basarab, Y.O.; Dobrobolska, O.V.; Vovk, I.M.; Loban’, G.A. Bacterial Factors of Cariogenicity (Literature Review). Wiad Lek. 2018, 71, 378–382. [Google Scholar]
- Risk Assessment (Laboratory Biosafety Manual, Fourth Edition and Associated Monographs); World Health Organization: Geneva, 2020; ISBN 978-92-4-001145-8.
- Basic Laboratory Procedures in Clinical Bacteriology; Vandepitte, J. , Verhaegen, J., Engbaek, K., Rohner, P., Piot, P., Heuck, C.C., Eds.; 2nd ed.; World Health Organization: Geneva, 2003; ISBN 978-92-4-154545-7. [Google Scholar]
- EUCAST. The European Committee on Antimicrobial Susceptibility Testing – EUCAST. Available online: https://www.eucast.org (accessed on 24 May 2025).
- Ananieva, M.M.; Faustova, M.O.; Basarab, I.O.; Loban’, G.A. Kocuria Rosea, Kocuria Kristinae, Leuconostoc Mesenteroides as Caries-Causing Representatives of Oral Microflora. Wiad Lek. 2017, 70, 296–298. [Google Scholar] [PubMed]
- Li, Q.; Huang, Y.; Wen, D.; Fu, R.; Feng, L. Application of Alkyl Polyglycosides for Enhanced Bioremediation of Petroleum Hydrocarbon-Contaminated Soil Using Sphingomonas Changbaiensis and Pseudomonas Stutzeri. Sci. Total. Environ. 2020, 719, 137456. [Google Scholar] [CrossRef]
- Lin, J.N.; Lai, C.H.; Chen, Y.H.; Lin, H.L.; Huang, C.K.; Chen, W.F.; Wang, J.L.; Chung, H.C.; Liang, S.H.; Lin, H.H. Sphingomonas Paucimobilis Bacteremia in Humans: 16 Case Reports and a Literature Review. J. Microbiol. Immunol. Infect. 2010, 43, 35–42. [Google Scholar] [CrossRef]
- Bhatia, R.; Tomar, J. Sphingomonas Paucimobilis - an Emerging Pathogen. Int. J. Contemp. Pediatr. 2016, 1123–1125. [Google Scholar] [CrossRef]
- Smalley, D.L. Enzymatic Profile of Pseudomonas Paucimobilis. J. Clin. Microbiol. 1982, 16, 564–565. [Google Scholar] [CrossRef] [PubMed]
- Ionescu, M.I.; Neagoe, D. Ștefan; Crăciun, A.M.; Moldovan, O.T. The Gram-Negative Bacilli Isolated from Caves—Sphingomonas Paucimobilis and Hafnia Alvei and a Review of Their Involvement in Human Infections. IJERPH 2022, 19, 2324. [Google Scholar] [CrossRef] [PubMed]
- Angelakis, E.; Roux, V.; Raoult, D. Sphingomonas Mucosissima Bacteremia in Patient with Sickle Cell Disease. Emerg. Infect. Dis. 2009, 15, 133–134. [Google Scholar] [CrossRef]
- Aleksejeva, V.; Dovbenko, A.; Kroiča, J.; Skadiņš, I. Toys in the Playrooms of Children’s Hospitals: A Potential Source of Nosocomial Bacterial Infections? Children 2021, 8, 914. [Google Scholar] [CrossRef]
- Bayram, N.; Devrim, İ.; Apa, H.; Gülfidan, G.; Türkyılmaz, H.N.; Günay, İ. Sphingomonas Paucimobilis Infections in Children: Nosocomial versus Community Acquired Infections. Mediterr. J. Hematol. Infect. Dis. 2013, 5, e2013040. [Google Scholar] [CrossRef]
- Maragakis, L.L.; Chaiwarith, R.; Srinivasan, A.; Torriani, F.J.; Avdic, E.; Lee, A.; Ross, T.R.; Carroll, K.C.; Perl, T.M. Sphingomonas Paucimobilis Bloodstream Infections Associated with Contaminated Intravenous Fentanyl. Emerg. Infect. Dis. 2009, 15, 12–18. [Google Scholar] [CrossRef]
- Azeredo, J.; Oliveira, R. The Role of Exopolymers in the Attachment of Sphingomonas Paucimobilis. Biofouling. 2000, 16, 59–67. [Google Scholar] [CrossRef]
- Al-Halawani, M.; Dazley, J.; Slim, J.; Boghossian, J. Sphingomonas Paucimobilis Bacteremia in an HIV and Hepatitis C Co-Infected Patient. Ir. J. Med. Sci. 2016, 185, 749–751. [Google Scholar] [CrossRef]
- Zeynali Kelishomi, F.; Mohammadi, F.; Khakpoor, M.; Malekmohammadi, R.; Nikkhahi, F. Isolation of Sphingomonas Paucimobilis from an Ocular Infection and Identification Using Ribosomal RNA Gene: First Case Report from Iran. Clin. Case. Rep. 2023, 11, e7715. [Google Scholar] [CrossRef]
- Souto, A.; Guinda, M.; Mera, A.; Pardo, F. Artritis séptica por Sphingomonas paucimobilis en un paciente inmunocompetente. Reumatología Clínica. 2012, 8, 378–379. [Google Scholar] [CrossRef]
- Aşkın, F.N.; Erinmez, M.; Ören, A.C.; Manay, A.B.; Zer, Y. Sphingomonas Paucimobilis Outbreak a Pediatric Hematology-Oncology Hospital: Epidemiological Investigation and Literature Review of an Emerging Healthcare-Associated Infection. Jpn. J. Infect. Dis. 2022, 75, 374–381. [Google Scholar] [CrossRef] [PubMed]
- Marincu, I.; Bratosin, F.; Bogdan, I.; Dumitru, C.; Stoica, C.N.; Csep, A.N.; Mederle, N.; Fericean, R.M.; Mederle, A.O.; Prathipati, R.; et al. Concurrent Sphingomonas Paucimobilis and Mycobacterium Tuberculosis Meningitis in an Immunocompromised Patient: A Rare Case Report and Comprehensive Review of Literature. Medicina. 2023, 59, 687. [Google Scholar] [CrossRef] [PubMed]
- Tito, E.; Ahmad, A.; Gongolli, J.; Issack, W.; Johnson, A. Sphingomonas Paucimobilis Bacteremia in a Patient With Retropharyngeal Abscess. Cureus. 2022, 14, e25407. [Google Scholar] [CrossRef] [PubMed]




| Antibiotic Tested | Diameter of growth retardation zones (mm) | ||
|---|---|---|---|
| Isolate No 1 | Isolate No 2 | Isolate No 3 | |
| Amoxicillin | 30 | 20 | 21 |
| Amoxicillin + Clavulanic acid | 35 | 30 | 32 |
| Ticarcillin + Clavulanic acid | 35 | 29 | 30 |
| Piperacillin Tazobactam | 34 | 27 | 27 |
| Ceftriaxone | 38 | 29 | 23 |
| Ceftazidime | 25 | 19 | 18 |
| Cefepime | 28 | 23 | 25 |
| Imipenem | 36 | 22 | 29 |
| Meropenem | 38 | 20 | 25 |
| Aztreonam | 10 | 10 | 11 |
| Tobramycin | 40 | 32 | 18 |
| Amikacin | 19 | 21 | 16 |
| Gentamicin | 29 | 20 | 15 |
| Cotrimoxazole | 32 | 21 | 19 |
| Rifampicin | 25 | 25 | 25 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).